To access all features of this site, you must enable Javascript. Here are the instructions for enabling Javascript in your web browser.
To carry out their activities, Research Teams of the Frédéric Joliot Institute for Life Sciences have developed high-profile technological platforms in many areas : biomedical imaging, structural biology, metabolomics, High-Throughput screening, level 3 microbiological safety laboratory...
All the news of the Institute of life sciences Frédéric Joliot
Le LEMM, en collaboration avec le LI2D et l’AP-HP, développe un test de diagnostic spécifique de la Covid-19 par spectrométrie de masse qui permettrait aussi la quantification de la charge virale du patient. Objectif à terme : adapter la méthode pour la rendre plus sensible et compatible avec les équipements d’analyse des hôpitaux.
By combining molecular dynamics and in vitro experiments, researchers at the LPSM (I2BC) have revealed the mode of action of sarcolipin in regulating the activity of SERCA1a, responsible for muscle relaxation.
A SCBM (DMTS) team, in collaboration with researchers at NeuroSpin and I2BC, is describing micellar nanometric vectors targeting tumors that have been imaged by fluorine magnetic resonance imaging (MRI). The observed 19F signal made it possible to precisely delimit the volume of the tumor zone in a mouse model and to quantify the probe accumulated in the target tissue.
Researchers from the LMC (DMTS), in collaboration with a team from AstraZeneca, have developed a labeling method, based on the exchange of carbon dioxide, simply using visible blue light and a photocatalyst.
The TIRO team (SHFJ), in collaboration with the neurovascular clinicians of the Nice and Marseille University Hospitals, carried out analyses of the metabolome of cerebral clots at the origin of the occlusion of a cerebral artery responsible for a cerebral vascular accident (stroke). A pilot study that improved the understanding of the complex relationship between blood glucose levels and patients' functional prognosis.
Jean-Luc Gennisson (BioMaps/SHFJ) coordinated, in partnership with the CEA-List (Sylvain Chatillon), the EchoBrain project (ATTRACT/H2020) aimed at adapting the digital tools developed by the List (CIVA platform) to significantly increase the quality of brain echography images, simple alternative compared to the methods (MRI, X-ray scanner) currently used for the diagnosis of strokes.
A study led by Oxford University researchers and involving researchers from the Institut Joliot (I2BC) and the University of Århus reveals the crucial role of the E340 residue in the inter-domain communication of the calcium transporter SERCA.
Coordinated by the Imagine Institute for Genetic Diseases, the ATRACTion program is based on a consortium of 11 academic and industrial partners, including SPI (DMTS), and aims to develop a precision medicine for patients with autoimmune and inflammatory diseases associated with primary immune deficiencies.
Top page
CEA is a French government-funded technological research organisation in four main areas: low-carbon energies, defense and security, information technologies and health technologies. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world.